Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
How Is the Bioconvergence Market Growth Forecast from 2025 to 2029?
The bioconvergence market size has grown rapidly in recent years. It will grow from $143.2 billion in 2024 to $158.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rise of personalized medicine, growth in biomedical engineering, increasing healthcare digitization, development of bioinformatics, and collaboration between technology and biotech industries.
The bioconvergence market size is expected to see rapid growth in the next few years. It will grow to $238.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to growth of regenerative medicine applications, rising prevalence of chronic diseases, adoption of bioelectronics and biosensors, development of engineered living materials and increase in investment in biotechnology research and development. Major trends in the forecast period include integration of artificial intelligence in drug discovery, development of lab-on-a-chip technologies, growth of wearable biosensors, expansion of three-dimensional (3d) bioprinting applications, utilization of nanorobotics for targeted therapies, adoption of organ-on-a-chip models and progress in gene editing techniques.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Bioconvergence Market?
The growing emphasis on personalized medicine is expected to propel the growth of the bioconvergence market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. Bioconvergence enhances personalized medicine by integrating advanced technologies with biological research, enabling more precise, individualized treatment plans tailored to a patient’s genetic and molecular profile. It improves healthcare outcomes by facilitating targeted therapies and reducing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growing emphasis on personalized medicine is driving the growth of the bioconvergence market.
Which Segment Offers the Highest Growth Opportunities in the Bioconvergence Market?
The bioconvergence market covered in this report is segmented –
1) By Component: Devices, Software, Services, Platforms
2) By Technology: Artificial Intelligence, Robotics, Three-Dimensional (3D) Printing, Nanotechnology, Synthetic Biology, Bioinformatics, Wearable Devices
3) By Application: Drug Discovery, Regenerative Medicine, Optogenetics, Nanorobotics For Drug Discovery, Diagnostic And Biological Sensors, Bioelectronics, Precision Medicine
4) By End-User: Pharmaceutical And Biotechnology Industry, Contract Research Organization, Other End Users
Subsegments:
1) By Devices: Diagnostic Devices, Therapeutic Devices, Wearable Medical Devices, Implantable Devices, Robotic Surgical Systems
2) By Software: Bioinformatics Software, Clinical Decision Support Systems, Genomic Data Analysis Tools, Imaging And Diagnostic Software, Laboratory Information Management Systems (LIMS)
3) By Services: Contract Research Services, Consulting And Integration Services, Data Management And Analysis Services, Custom Software Development, Regulatory And Compliance Services
4) By Platforms: Artificial Intelligence Platforms, Omics Integration Platforms, Digital Health Platforms, Personalized Medicine Platforms, Cloud-Based Analytics Platforms
What Are the Key Industry Trends Transforming the Bioconvergence Market?
Major companies operating in the bioconvergence market are focusing on developing innovative products, such as automated miniaturized single-cell proteomics sample preparation, to enable precise protein analysis, reduce sample loss, and streamline workflows in single-cell research. Automated miniaturized single-cell proteomics sample preparation is a process that uses automation to handle and prepare proteins from individual cells in ultra-low volumes. For instance, in September 2022, Scienion GmbH, a Germany-based biotechnology company, launched proteochip LF 48 to enable reproducible and miniaturized workflows for mass spectrometry-based single-cell proteomics analysis. This innovative bioconvergence tool enables on-chip lysis and protein digestion of individual cells, allowing researchers to reduce sample loss, streamline workflows, and gain deeper biological insights through efficient mass spectrometry analysis. The proteochip LF 48 is highly versatile, offering effective sample preparation for diverse single-cell proteomics applications by combining precise cell handling with on-chip lysis and protein digestion for improved workflow efficiency and data quality.
Who Are the Key Players Driving the Bioconvergence Market?
Major companies operating in the bioconvergence market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Veolia Environnement S.A, Novartis AG, Eli Lilly and Company, Amgen Inc., HDR Inc., Ginkgo Bioworks, BICO Group AB, MeMed Diagnostics Ltd., Anima Biotech, Singota Solutions LLC, SetPoint Medical Corporation, Galvani Bioelectronics, Ezassi Inc., Tissue Dynamics Ltd., Sanara Ventures Ltd., BioConvergent Health LLC, Gradiant Bioconvergence Center
Get the full bioconvergence market report here:
What Are the Regional Insights for the Bioconvergence Market Forecast?
North America was the largest region in the bioconvergence market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioconvergence market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment